Next-generation sequencing panel for comprehensive analysis of BRCA1 and BRCA2 genes. Identifies pathogenic variants to assess hereditary breast and ovarian cancer risk.
Manufactured by
India
3B BlackBio Dx Group is one of India's leading companies in PCR-based molecular diagnostics, incorporated in November 2010. As an ISO 13485:2016 certified and GMP compliant biotech R&D organization, the Group is engaged in the design, development, manufacturing, and commercialization of PCR-based Molecular Diagnostic Kits, PCR Enzymes, and PCR Reagents, marketed under its flagship brand TRUPCR® to renowned diagnostic labs across India and beyond. With a highly trained R&D team experienced across multiple disease parameters, the Group has the capability to develop new diagnostic solutions in a remarkably short span of time. The Group's global footprint is strengthened through its subsidiaries - TRUPCR Europe and Coris BioConcept. TRUPCR Europe manufactures and supplies high-quality qPCR and NGS molecular diagnostic products worldwide, backed by a team with over 30 years of experience in the molecular diagnostics and healthcare sectors. Coris BioConcept, based in Belgium and a recognized expert in rapid in vitro diagnostics since 1996, develops and markets IVD kits for respiratory, gastroenteric, and blood-borne pathogens, as well as pioneering assays for Anti-Microbial Resistance detection, including the innovative RESIST range and BL-RED technology. Both companies are CE marked and ISO 13485 certified, with Coris BioConcept's products distributed across more than 60 countries worldwide. 3B BlackBio Dx Group combines deep R&D expertise, cutting-edge technology, and decades of clinical experience to deliver innovative and reliable diagnostic solutions across the globe. Committed to enhancing laboratory efficiency and improving patient care, the Group offers comprehensive technical support and training, making it a trusted partner for diagnostic laboratories and healthcare institutions worldwide.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
TRUPCR Europe Ltd
United Kingdom · 8 relevant products
Yaneng BIOscience (Shenzhen) Co.,Ltd.
China · 10 relevant products
AITbiotech Pte Ltd
Singapore · 1 relevant product
Wuhan YZY Medical Science and Technology Co.,Ltd.
China · 5 relevant products
Medicover Genetics Ltd
Cyprus · 4 relevant products
CLONIT SRL
Italy · 2 relevant products
GENETRON HEALTH (BEIJING) CO., LTD
China · 3 relevant products
PlexBio Co., Ltd.
Taiwan · 1 relevant product
Axbio (shenzhen) Co.,LTD
China · 3 relevant products
Xi'an Tianlong Science And Technology Co., Ltd
China · 1 relevant product
46 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →12 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 113 closest product alternatives
TRUPCR Europe Ltd · United Kingdom
A next-generation sequencing panel kit for comprehensive BRCA gene analysis. This kit enables detection of BRCA1 and BRCA2 mutations relevant to hereditary breast and ovarian cancer risk assessment.
TRUPCR Europe Ltd · United Kingdom
A next-generation sequencing panel kit for detecting mutations associated with endometrial cancer. This kit enables identification of genetic alterations relevant to endometrial cancer diagnosis and management.
TRUPCR Europe Ltd · United Kingdom
A next-generation sequencing panel kit designed for comprehensive analysis of solid tumor mutations. This kit identifies genetic alterations relevant to solid tumor diagnosis and targeted therapy selection.
TRUPCR Europe Ltd · United Kingdom
A next-generation sequencing panel kit designed for comprehensive analysis of myeloid malignancies. This kit identifies genetic alterations relevant to diagnosis and monitoring of hematologic disorders.
Yaneng BIOscience (Shenzhen) Co.,Ltd. · China
Molecular testing kit for detecting breast cancer-related genetic alterations, enabling risk stratification and clinical decision-making in oncology care.
Yaneng BIOscience (Shenzhen) Co.,Ltd. · China
Nucleic acid detection kit for screening breast cancer-related genetic markers. Enables risk stratification for breast cancer predisposition assessment.
AITbiotech Pte Ltd · Singapore
Next-generation sequencing testing kit for comprehensive genomic analysis and variant detection. Enables high-throughput sequencing for applications in molecular diagnostics and research.
Wuhan YZY Medical Science and Technology Co.,Ltd. · China
Diagnostic kit for analyzing cancer-related genetic mutations and biomarkers. Provides genomic information to support targeted therapy selection and treatment planning.
Yaneng BIOscience (Shenzhen) Co.,Ltd. · China
Molecular diagnostic kit for detecting colorectal cancer-associated genetic alterations. Provides genetic risk assessment for colorectal malignancy.
Medicover Genetics Ltd · Cyprus
Next-generation non-invasive prenatal testing kit for screening common genetic conditions in singleton, twin, and IVF pregnancies. Utilizes proprietary sequencing technology with automated workflow capabilities for high-throughput prenatal screening.
CLONIT SRL · Italy
A diagnostic test kit for detecting the MTR A2756G mutation associated with genetic predisposition to thrombophilia. The kit contains reagents for 32 tests and is used in cardiovascular disease assessment. It is CE Mark certified.
GENETRON HEALTH (BEIJING) CO., LTD · China
A diagnostic kit based on GENETRON's proprietary 'one-step method' technology enabling completion of library construction in 1.5 to 3 hours (China patent ZL 201710218529.4). It detects EGFR, KRAS, BRAF, HER2, and PIK3CA gene mutations in DNA and ALK and ROS1 gene fusions in RNA from FFPE tissue samples of non-small cell lung cancer patients, as well as MET gene 14 exon skipping mutations.
101 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products